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Abstract  
Background: High resting heart rate has been associated with increased risk of type 2 diabetes 
in several studies, but the available data are not consistent and it is unclear if there is a dose-
response relationship between resting heart rate and type 2 diabetes risk. We aimed to clarify 
this association by conducting a systematic review and meta-analysis of published studies.  
 
Methods and results: PubMed, Embase and Ovid Medline databases were searched for 
prospective studies published up until October 11th, 2013. Summary relative risks were 
estimated using a random effects model. Ten cohort studies with a total of 5,628 cases and 
119,915 participants were included. The summary RR for high vs. low resting heart rate was 
1.83 (95% CI: 1.28-2.60, I2=88%, n=7), and in the dose-response analysis the summary RR 
was 1.20 (95% CI: 1.07-1.34, I2=93%, n=9) for an increase of 10 beats per minute. The 
heterogeneity was to a large degree explained by two studies. There was evidence of 
nonlinear associations between resting heart rate (pnonlinearity<0.0001) and risk of type 2 
diabetes.   
 
Conclusion: The current meta-analysis indicates a strong positive association between high 
resting heart rate and the risk of type 2 diabetes. As a non-invasive marker of type 2 diabetes 
risk, resting heart rate may have potential in the clinical setting, especially for interventions 
aimed at lowering the risk of type 2 diabetes. Additional studies are needed to clarify the 
mechanisms that may be responsible for the association between resting heart rate and type 2 
diabetes.  
 
Key words: Resting heart rate, type 2 diabetes, systematic review, meta-analysis. 
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Introduction 
 Several previous epidemiological studies have linked elevated resting heart rate to 
increased risk of cardiovascular disease and all-cause mortality (1;2). Resting heart rate is 
known to be a sensitive indicator of the autonomic nervous system,(3) and it is possible that 
an imbalance between parasympathetic and sympathetic activity might contribute towards the 
observed association between a raised resting heart rate and type 2 diabetes. Increased 
sympathetic tone not only elevates resting heart rate, but also amplifies insulin resistance,(4) 
which might suggest an intermediary role for impaired autonomic nervous activity in the 
relationship between resting heart rate and type 2 diabetes. Alternatively, metabolic 
syndrome, abdominal obesity and insulin resistance may activate the sympathetic nervous 
system, with elevated heart rate being a consequence rather than a cause of the metabolic 
alterations (5).  
Despite this, the association between elevated resting heart rate and type 2 diabetes 
remains unclear (6-17). Some studies suggested an increased risk of type 2 diabetes with 
higher heart rate (6;7;10;12-17), whereas others found the association to be no longer 
significant after adjustment for potential confounding factors (8;9;11). These studies were, 
however, largely heterogeneous with regards to the strength of the association; some reported 
a 60-100% increase in the risk (6;7;13-15) and others up to a 5-fold increase (14) in risk with 
elevated heart rate.  
Hence, we conducted a systematic review and meta-analysis of prospective studies 
that examined the relationship between resting heart rate and type 2 diabetes. Specifically we 
aimed to: 1) clarify the strength of the association, 2) determine whether there is a dose-
response relationship, and 3) establish whether the association varies by adjustment for 
potential confounding factors and other study characteristics. 
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Methods  
Search strategy 
We searched the electronic databases PubMed, Embase and Ovid Medline databases up until 
October 11th 2013 for prospective studies of resting heart rate and type 2 diabetes risk. We 
used the following search terms for the search: (“resting heart rate” OR “heart rate” OR 
“resting pulse”) AND “diabetes” with search fields “title/abstract” and “MeSH terms”. No 
language restrictions were imposed. We also examined the reference lists of the studies 
included in the analysis in an effort to identify additional potentially relevant studies. All 
retrieved citations were screened by 2 independent reviewers (D.A. and B.H.) and any 
disagreements were resolved by consensus among authors.  
 
Study selection 
Studies were included in the analyses based on the following inclusion criteria: the study had 
to: 1) have a prospective cohort, case-cohort or nested case-control design from the general 
population (no studies of high-risk patients with hypertension or cardiovascular disease were 
included), 2) investigate the association between resting heart rate and risk of type 2 diabetes, 
3) present estimates of the relative risk (RR), such as hazard ratios, risk ratios, or odds ratios 
with the 95% confidence intervals (95% CI), and 4) for the dose-response analysis, a 
quantitative measure of the heart rate and the total number of cases and person-years or 
participants had to have been available in the publication. We contacted the authors of two 
studies (6;7) to obtain more detailed results so the studies could be included in the dose-
response analysis, and received more detailed data from one study (6). 
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Data extraction 
We extracted the following data from each study: The first author’s last name, publication 
year, country where the study was conducted, the study name, follow-up period, sample size, 
gender, age, number of cases, exposure, resting heart rate level, RRs and 95% CIs for the 
association and variables adjusted for in the analysis.  
 
Statistical methods 
We used random effects models to calculate summary RRs and 95% CIs for the highest vs. 
the lowest level of resting heart rate and also for the dose-response analysis (18). The average 
of the natural logarithm of the RRs was estimated and the RR from each study was weighted 
by the inverse of its variance and then un-weighted by a variance component which 
corresponds to the amount of heterogeneity in the analysis. A two-tailed p<0.05 was 
considered statistically significant. For the two studies which reported results separately for 
men and women (14) or by treatment group (10), we combined the results using a fixed-
effects model to obtain an overall estimate which was used for the main analysis.  
 The method described by Greenland and Longnecker (19) was used for the dose–
response analysis and study-specific slopes (linear trends) and 95% CIs from the natural logs 
of the RRs and CIs were computed across categories of resting heart rate. This method 
requires that the distribution of cases and person-years or non-cases and the level of resting 
heart rate and RRs with the variance estimates for at least three quantitative exposure 
categories are known. We estimated the distribution of person-years in studies that did not 
report these. For one study we divided the total number of participants by four to get the 
approximate number of participants for each quartile (11). For four studies (11-13;15) we 
multiplied the mean or median duration of follow-up by the number of participants in each 
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category to get an estimate of the number of person-years for each category. Importantly, 
because these estimated numbers are only used as starting points for the glst-iterations they 
do not affect the estimated dose-response slopes (we also repeated the analyses using slightly 
different numbers of person-years, but this led to identical results). The median or mean 
resting heart rate level in each category was assigned to the corresponding relative risk for 
each study. When resting heart rate was reported as ranges we estimated the midpoint for 
each category by calculating the average of the lower and upper bound. When the highest or 
lowest category was open-ended or had extreme upper cut-off points we assumed the open-
ended interval length to be the same as the adjacent interval. A potential nonlinear dose-
response relationship between resting heart rate and type 2 diabetes was examined using 
fractional polynomial models (20). We determined the best fitting second order fractional 
polynomial regression model, defined as the one with the lowest deviance. A likelihood ratio 
test was used to assess the difference between the nonlinear and linear models to test for 
nonlinearity (20).  
 Study quality was assessed using the Newcastle-Ottawa scale which measures study 
quality based on representativeness of the exposed cohort, selection of the non-exposed 
cohort, ascertainment of exposure, demonstration that the outcome was not present at the start 
of the study, comparability of cohorts (adjustment or matching for two different risk factors), 
assessment of outcome, duration of follow-up, and adequacy of follow-up and gives a 
maximum of nine stars (21). We grouped studies with 0-3 stars, 4-6 stars, and 7-9 stars for 
the subgroup analysis.  
 We assessed heterogeneity between studies using the Q test and I2 (22). I2 is the 
amount of total variation that is explained by between study variation. I2 values of 
approximately 25%, 50% and 75% are considered to reflect low, moderate and high 
heterogeneity, respectively. Subgroup analyses were conducted to investigate potential 
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sources of heterogeneity including duration of follow-up, gender, geographic location, 
number of cases, study quality, adjustment for confounding factors, and exclusion of subjects 
using hypertensive or cardiovascular disease medications or with diagnosed cardiovascular 
disease at baseline.  
Publication bias was assessed with Egger’s test (23) and the results were considered 
to indicate publication bias when p<0.10. We conducted sensitivity analyses excluding one 
study at a time to ensure that the results were not simply due to one large study or a study 
with an extreme result. Results from these sensitivity analyses are presented excluding the 
two studies with the largest negative and positive impact on the summary estimates. The 
statistical analyses were conducted using Stata, version 10.1 software (StataCorp, College 
Station, TX, USA). 
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Results 
Main results 
We identified 10 cohort studies of healthy general populations (6-15) that were included in 
the meta-analysis of resting heart rate and type 2 diabetes (Table 1, Figure 1) and these 
included a total of 5,628 cases and 119,915 participants. Two studies (16;17) of hypertensive 
patients and cardiovascular disease patients were excluded from the analysis. The summary 
RR for high vs. low resting heart rate was 1.83 (95% CI: 1.28-2.60, n=7) (Supplementary 
Figure 1), but there was substantial heterogeneity, I2=88%, pheterogeneity<0.0001. The summary 
RR ranged from 1.71 (95% CI: 1.20-2.44) when excluding the study by Nagaya et al. (14) to 
1.99 (95% CI: 1.64-2.40) when excluding the study by Carnethon et al. (11). Heterogeneity 
was no longer significant when the latter study was excluded, I2=30%, pheterogeneity=0.21.  
The summary RR for each 10 beats per minute increment in resting heart rate was 1.20 (95% 
CI: 1.07-1.34, n=9) (Figure 2a), but there was substantial heterogeneity, I2=93%, 
pheterogeneity<0.0001. The summary RR ranged from 1.14 (95% CI: 1.06-1.23) when the study 
by Nagaya et al. (14) was excluded to 1.23 (95% CI: 1.10-1.38) when the study by Carnethon 
et al. (11) was excluded. Heterogeneity was reduced when both of these outlying studies were 
excluded (11;14), but the summary estimate remained similar, summary RR=1.17 (95% CI: 
1.09-1.26, I2=59%, pheterogeneity=0.02). There was no evidence of publication bias with Egger’s 
test, p=0.42, although the number of studies was low. There was no substantial evidence of 
asymmetry in the funnel plot (Supplementary Figure 2). The nonlinear dose-response analysis 
requires at least three categories of resting heart rate, so studies that only reported a 
continuous estimate could not be included, so in total six studies were included in the 
nonlinear dose-response analysis (11-15). There was evidence of a nonlinear association 
between resting heart rate and risk of type 2 diabetes, pnonlinearity<0.0001, with the slope 
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leveling off at higher levels (Figure 2b). Study quality as assessed by the Newcastle-Ottawa 
scale was in general high with a range from 5-9 stars out of 9 possible and a median of 7.5 
stars (Supplemental Table 2) and there was no evidence of heterogeneity by study quality 
scores (Table 2).  
 
Subgroup, sensitivity and meta-regression analyses 
In subgroup and meta-regression analyses we found no significant heterogeneity between 
subgroups when studies were stratified by gender, duration of follow-up, geographic location, 
or study size (Table 2), although the associations did not always persist across subgroups. 
Further subgroup analyses according to whether studies had adjusted for confounding factors 
didn’t reveal significant heterogeneity between strata, although associations were not always 
statistically significant. There was also no significant heterogeneity between subgroups of 
studies with or without exclusion of hypertensive medication users, cardiovascular 
medication users or persons with prevalent cardiovascular disease at baseline (Table 2). For 
one study reporting results from a randomized trial with three groups (placebo, metformin 
treatment, and lifestyle intervention) (10) we conducted a further sensitivity analysis using 
only the results from the placebo group in the meta-analysis, but the results remained similar, 
summary RR=1.20 (95% CI: 1.06-1.35, I2=93%, pheterogeneity<0.0001).  
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Discussion: To our knowledge this is the first meta-analysis on the relationship between 
resting heart rate and risk of type 2 diabetes. We found a high vs. low resting heart rate was 
associated with an 83% increase in the RR of type 2 diabetes. Moreover the dose-response 
analysis showed the RR increased 19% for every 10 beats per minute increment in resting 
heart rate. The association appeared to be nonlinear, and leveled off at higher values of 
resting heart rate.  
 Several biological mechanisms could explain the association between resting heart 
rate and type 2 diabetes. An elevated resting heart rate may reflect an imbalance in the 
autonomic nervous system favouring sympathetic activation. Indeed, sympathetic over-
activity has been linked with reduced insulin sensitivity, high blood pressure, obesity, 
inflammation and the metabolic syndrome (12;24-27), all of which increases the risk of type 
2 diabetes. Further, the pancreas is heavily innervated by parasympathetic nerve fibers, which 
stimulate β-cells of the pancreas to release insulin in response to increasing blood glucose 
levels. On the other hand sympathetic stimulation inhibits the secretion of insulin from 
pancreatic β-cells. Moreover, some evidence proposes that sympathetic activation might 
contribute to insulin resistance by inducing haemodynamic and cellular effects (28). 
Sympathetic activation causes vasoconstriction and decreases skeletal muscle blood flow, 
leading to impaired glucose uptake in skeletal muscle (29). Further, epinephrine causes 
hyperglycaemia by reducing the insulin-mediated glucose uptake in skeletal muscle cells, 
while β-adrenergic receptor blockade seems to abolish this effect (30). Sympathetic 
overactivity also stimulates the renin-angiotensin-aldosterone system, which increases heart 
rate and may be implicated in insulin resistance (31;32). In support of this are results from 
some randomized trials which have shown that patients treated with ACE inhibitors or 
angiotensin receptor blockers have a lower risk of type 2 diabetes compared to control 
patients (33-36), however, not all studies have been consistent (37).   
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Some evidence reported that chronic sympathetic overactivity may facilitate the 
development of obesity by downregulating the β-adrenoceptor-mediated thermogenic 
response (38;39). The relationship between sympathetic activation and insulin resistance may 
also be reciprocal. Elevated glucose levels, even in the non-diabetic range can damage 
peripheral nerve fibers, leading to increased sympathetic activity and reduced 
parasympathetic control (40-42). Thus, it is possible that an elevated resting heart rate could 
be a consequence, and equally, a marker of insulin resistance. In this meta-analysis, the 
association between resting heart rate was attenuated in subgroup analysis of the studies that 
adjusted for baseline glucose or HOMA-IR. These findings suggest that baseline glucose 
and/or insulin resistance accounts for part, though not all of the association, as the positive 
relationship between elevated resting heart rate and type 2 diabetes persisted in the studies 
with such adjustment. The potential mechanism that could explain the nonlinear association 
between resting heart rate and type 2 diabetes are yet to be fully clarified.   
Some potential limitations of this meta-analysis should be mentioned. There was high 
heterogeneity both in the high vs. low analysis and the dose-response analysis, although this 
appeared to be largely explained by one (14) and two (11;14) studies , respectively. When 
both studies were excluded the heterogeneity was substantially reduced in the high vs. low 
analysis and it was lower in the dose-response analysis as well. In this meta-analysis it is 
possible that unmeasured or residual confounding may have influenced the association 
between elevated resting heart rate and type 2 diabetes. Indeed, high resting heart rate may be 
associated with other risk factors for type 2 diabetes including obesity, hypertension, 
smoking, and a sedentary lifestyle (12;43). Nevertheless, many of the studies included in this 
meta-analysis adjusted for known confounding factors such as age, BMI, smoking, and 
physical activity. The results persisted in most, but not all subgroup analyses, possibly due to 
few studies in some strata. However, more importantly we found no evidence of 
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heterogeneity between these subgroups with meta-regression analyses. Use of anti-
hypertensive and cardiovascular disease medications can affect heart rate and could 
potentially have influenced the results, however, the results persisted in several subgroup 
analyses where persons using such medications and/or persons with cardiovascular disease at 
baseline had been excluded.  
 Publication bias may also have affected the results, albeit, in this study we found no 
evidence of publication bias with the statistical tests and there was no evidence of asymmetry 
when inspecting the funnel plots, although the number of studies was moderate.  
 Our meta-analysis has several strengths. Combining the evidence from all available 
studies increased the statistical power to detect an association between elevated resting heart 
rate and type 2 diabetes. We conducted high vs. low analyses, and linear and nonlinear dose-
response analyses to clarify the strength and the shape of the dose-response relationship 
between resting heart rate and type 2 diabetes. We also conducted a number of subgroup and 
sensitivity analyses and the association persisted across most strata of study characteristics. 
Lastly the study quality was high and ranged from 5-9, with a median of 7.5 out of 9 stars.  
 In conclusion, the current meta-analysis found a positive association between resting 
heart rate and risk of type 2 diabetes. As a non-invasive marker, the resting heart rate may 
have potential in the clinical setting, particularly for interventions aimed at reducing the risk 
of type 2 diabetes. Additional studies are needed to disentangle the causal mechanisms that 
may be responsible for the association between resting heart rate and type 2 diabetes.   
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Table 1: Prospective cohort studies of resting heart rate and type 2 diabetes risk 
 
Author, 
publication 
year, country 
Study name Follow-up 
period 
Study size, 
gender, age, 
number of cases 
 
Study quality Exposure and subgroup Quantity RR (95% CI) Adjustment for confounders 
Grantham NM 
et al, 2013, 
Australia 
Australian 
Diabetes 
Obesity and 
Lifestyle study 
1999-2000 – 
2004-2005, 
5 years 
follow-up 
5817 men and 
women, age ≥25 
years: 221 cases 
8 Heart rate, all 
 
 
 
Heart rate, men 
 
 
 
Heart rate, women 
<60 BPM 
60-69 
70-79 
≥80 
<60 BPM 
60-69 
70-79 
≥80 
<60 BPM 
60-69 
70-79 
≥80 
1.00 
1.55 (0.89-2.67) 
1.44 (0.83-2.51) 
1.89 (1.07-3.35) 
1.00 
2.01 (0.99-4.09) 
1.54 (0.73-3.25) 
2.02 (0.93-4.39) 
1.00 
1.03 (0.42-2.50) 
1.25 (0.53-2.94) 
1.72 (0.72-4.12) 
Age, family history of diabetes, 
waist circumference, hip 
circumference, smoking status, 
education, physical activity, 
cholesterol, HDL cholesterol, 
triglycerides, hypertension, 
hypertension treatment, 
cardiovascular disease history, 
homeostasis model assessment 
of insulin sensitivity, urinary 
albumin creatinine ration, 
anxiety, total population also 
adjusted for sex 
Nagaya T et 
al, 2010, Japan 
Gifu Prefecture 
Center for 
Health Check 
and Promotion  
1988-1991 – 
NA, 7.3 
years 
follow-up 
16828 men and 
8368 women, 
age 30-59 years: 
869/224 cases 
8 Heart rate, men 
 
 
 
 
Heart rate, women 
32-53 BPM 
54-58 
59-64 
65-131 
Per 8.9 BPM 
36-57 BPM 
58-62 
63-67 
68-137 
Per 9.3 BPM 
1.00 
1.25 (1.00-1.56) 
1.63 (1.32-2.01) 
2.26 (1.84-2.78) 
1.37 (1.29-1.45) 
1.00 
1.09 (0.72-1.64) 
1.06 (0.70-1.62) 
2.06 (1.43-2.96) 
1.46 (1.31-1.62) 
Age, BMI, smoking, drinking, 
exercise, education 
Zhang X et al, 
2010, China 
Shanghai 
Women’s 
Health Study 
2000-2002 – 
NA, 4.9 
years 
follow-up 
47571 women, 
age 40-70 at 
baseline: 849 
cases 
7 Resting heart rate ≤68 BPM 
69-72 
73-76 
77-80 
>80 
1.00 
1.21 (0.99-1.47) 
1.30 (1.05-1.62) 
1.37 (1.12-1.69) 
1.60 (1.28-2.00) 
Age, education, occupation, 
family income, cigarette 
smoking, alcohol, BMI 
Shigetoh Y et 
al, 2009, Japan 
Tanashimaru – 
Seven Countries 
Study 
1979 – 1999, 
20 years 
follow-up 
637 men and 
women, age >20 
years: 8 cases 
6 Heart rate <60 BPM 
60-69 
70-79 
≥80 
1.00 
2.15 (0.68-6.76) 
2.91 (0.89-9.53) 
5.39 (1.34-21.8) 
Age, sex, BMI, fasting plasma 
glucose 
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Carnethon MR 
et al, 2008, 
USA 
Chicago Heart 
Association 
Detection 
Project in 
Industry 
1992-2002, 
10 years 
follow-up 
14992 men and 
women, age 35-
64 years: 1877 
cases 
8 Heart rate 
 
 
 
 
Heart rate 
<68 BPM 
68-74 
75-83 
≥84 
Per 12 BPM 
<68 BPM 
68-74 
75-83 
≥84 
Per 12 BPM 
1.00 
1.07 (0.92-1.23) 
1.07 (0.92-1.24) 
1.19 (1.03-1.38) 
1.07 (1.02-1.12) 
1.00 
1.04 (0.90-1.21) 
1.02 (0.88-1.19) 
1.02 (0.88-1.19) 
1.00 (0.95-1.06) 
Age, sex, cigarette smoking, 
education, years of Medicare 
eligibility, BMI 
 
 
 
+ glucose 
Carnethon MR 
et al, 2006, 
USA 
Diabetes 
Prevention 
Programme 
1996-2001, 
3.2 years 
follow-up 
2980 men and 
women, age ≥25 
years: NA 
5 Heart rate, placebo group 
Heart rate, metformin 
group 
Heart rate, lifestyle 
group 
Per 11 BPM 
Per 11 BPM 
 
Per 11 BPM 
1.09 (0.97-1.22) 
1.17 (1.03-1.35) 
 
1.19 (1.02-1.40) 
Age, race, sex, baseline weight, 
weight change 
Nilsson PM et 
al, 2004, 
Sweden 
Malmø 
Preventive 
Project  
1974-1984 – 
1994-1996, 
16.4 years 
follow-up 
6599 men, age 
35-51 years: 
281 cases 
7 Heart rate Per 10 BPM 1.13 (0.99-1.30) Age, sleep disturbances, systolic 
and diastolic blood pressure, 
antihypertensive medication, 
fasting whole blood glucose, 
BMI, change in BMI from 
baseline, follow-up time, 
diabetes heredity, smoking, 
physical activity, social class 
Carnethon MR 
et al, 2003, 
USA 
Atherosclerosis 
Risk in 
Communities 
Study 
1987-1998, 
8.3 years 
follow-up 
8185 men and 
women, age 45-
64 years: 1063 
cases 
8 Heart rate 
 
 
Heart rate 
Per 9.7 BPM 
 
 
Per 9.7 BPM 
1.18 (1.11-1.26) 
 
 
1.06 (1.00-1.13) 
Age, race, study center, 
education, alcohol, smoking, 
prevalent coronary heart 
disease, physical activity, BMI 
+baseline glucose 
Perry IJ et al, 
1995, United 
Kingdom 
British Regional 
Heart Study 
1978-1980 – 
1991, 12.8 
years 
follow-up 
7097 men, age 40-
59 years: 178 
cases 
 
9 Heart rate Quintile 5 vs. 1 2.2 (1.1-4.2) Age, BMI, coronary heart 
disease, physical activity, 
alcohol, systolic blood pressure, 
HDL cholesterol, smoking, uric 
acid 
Feskens EJM et 
al, 1989, 
Netherlands  
The Zutphen 
Study 
1960-1985, 
25 years 
follow-up 
841 men, age 40-
59 years: 58 cases 
8 Heart rate Quartile 4 vs. 1 2.0 (1.1-3.7) Age, subscapular skinfold, 
cigarette use, alcohol, energy 
intake 
 
BMI=Body Mass Index, HDL=high density lipoprotein  
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Table 2: Subgroup analyses of resting heart rate and type 2 diabetes risk, dose-response analysis 
 Resting heart rate, per 10 bpm 
 n RR (95% CI) I2 (95% CI)  Ph1 Ph2 
All studies 9 1.20 (1.07-1.34) 92.9 (89.0-96.0) <0.0001  
Duration of follow-up      
    <10 yrs follow-up 5 1.21 (1.05-1.39) 93.3 (87.0-96.0) <0.0001 0.75 
    ≥10 yrs follow-up 4 1.18 (0.99-1.39) 78.9 (43.0-92.0) 0.003 
Gender4      
   Men 4 1.27 (1.10-1.46) 73.4 (25.0-91.0) 0.01 0.11/ 
0.503 
   Women 3 1.37 (1.22-1.54) 48.8 (0-85.0) 0.14 
   Men and women 5 1.08 (1.01-1.17) 72.2 (30.0-89.0) 0.006 
Geographic location       
    Europe 2 1.20 (1.02-1.41) 40.2 (NC) 0.20 0.38 
    America 3 1.06 (0.99-1.13) 75.3 (18.0-93.0) 0.02 
    Asia 3 1.41 (1.29-1.53) 32.2 (0-93.0) 0.23 
    Australia 1 1.16 (0.99-1.36)   
Number of cases4      
    Cases <500 4 1.22 (1.08-1.36) 28.5 (0-74.0) 0.24 0.68 
    Cases ≥500 4 1.19 (0.98-1.44) 97.2 (95.0-98.0) <0.0001 
Study quality      
  0-3 stars 0    0.78 
  4-6 stars 2 1.28 (0.91-1.80) 69.8 (NC) 0.07 
  7-9 stars 7 1.19 (1.04-1.37) 94.5 (91.0-97.0) <0.0001 
Adjustment for confounding factors 
Age  Yes  9 1.20 (1.07-1.34) 92.9 (89.0-96.0) <0.0001 NC 
No 0    
Education  Yes  5 1.18 (1.00-1.40) 96.3 (94.0-98.0) <0.0001 0.74 
No 4 1.19 (1.07-1.32) 43.7 (0-81.0) 0.15 
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Body mass index, weight Yes  7 1.19 (1.05-1.36) 94.6 (91.0-97.0) <0.0001 0.76 
No  2 1.22 (1.07-1.40) 7.5 (NC) 0.30 
Glucose or HOMA-IS Yes  5 1.08 (1.00-1.17) 65.0 (8.0-87.0) 0.02 0.11 
No  4 1.29 (1.12-1.50) 90.0 (77.0-96.0) <0.0001 
Physical activity, fitness Yes  4 1.19 (0.99-1.44) 94.4 (89.0-97.0) <0.0001 0.99 
No  5 1.19 (1.05-1.35) 86.2 (70.0-94.0) <0.0001 
Alcohol  Yes 4 1.28 (1.06-1.53) 94.2 (88.0-97.0) <0.0001 0.22 
No  5 1.11 (1.01-1.22) 74.2 (36.0-90.0) 0.004 
Smoking  Yes 7 1.19 (1.04-1.37) 94.5 (91.0-97.0) <0.0001 0.78 
No 2 1.28 (0.91-1.80) 69.8 (NC) 0.07 
Hypertension  Yes  2 1.14 (1.03-1.27) 0 (NC) 0.81 0.66 
No 7 1.22 (1.07-1.39) 94.7 (91.0-97.0) <0.0001 
Exclusion of subjects  
Subjects using hypertensive medication 
were excluded 
Yes  5 1.26 (1.08-1.46) 93.4 (88.0-97.0) <0.0001 0.33 
No 4 1.12 (0.99-1.27) 72.5 (22.0-90.0) 0.01 
Subjects using cardiovascular disease 
medications were excluded 
Yes  3 1.20 (0.99-1.46) 96.6 (93.0-98.0) <0.0001 0.96 
No 6 1.20 (1.05-1.36) 82.4 (63.0-92.0) <0.0001 
Subjects with prevalent cardiovascular 
disease at baseline were excluded 
Yes  3 1.28 (1.08-1.53) 93.4 (84.0-97.0) <0.0001 0.21 
No 6 1.11 (1.02-1.21) 69.7 (29.0-87.0) 0.006 
Subjects with prevalent cardiovascular 
disease at baseline or users of 
cardiovascular disease medications 
Yes  4 1.22 (1.04-1.44) 94.9 (90.0-97.0) <0.0001 0.66 
No 5 1.16 (1.02-1.33) 75.2 (39.0-90.0) 0.003 
 
n denotes the number of studies.  
1
 P for heterogeneity within each subgroup,  
2
 P for heterogeneity between subgroups with meta-regression analysis,  
3
 P for heterogeneity between men and women (studies with genders mixed were excluded) 
4
 The number of studies is not equal to the total because some studies reported both on men and women 
combined and separately or because of missing information regarding the number of cases 
NC = not calculable  
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Figure 1. Flow-chart of study selection 
 
7552 records identified in total up to 11.10.2013
2086 records identified in the PubMed database
3301 records identified in the Embase database
2165 records identified in the Ovid Medline database
16 given detailed assessment
7538 excluded based on
information in title or 
abstract
4 studies excluded
2 cross-sectional studies
2 studies of heart rate 
recovery as exposure
12 studies included
11 cohort studies 
1 randomized trial
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Figure 2. Resting heart rate and type 2 diabetes, linear (a) and nonlinear (b) dose-response 
analysis. The reference category in the nonlinear dose-response analysis was the lowest 
estimated midpoint among the included studies. References number 6, 11-15 were included in 
the nonlinear analysis.  
 
A
B
1
1.5
2
2.5
3
4
RR
50 60 70 80 90
Resting heart rate (beats/min)
Best fitting fractional polynomial
95% confidence interval
Resting heart rate and type 2 diabetes, nonlinear dose-response
Resting heart rate and type 2 diabetes, linear dose-response, per 10 bpm
 
 Relative Risk
 .5  .75  1  1.5  2  3  5
 Study
 Relative Risk
 (95% CI)
 Grantham, 2013 [15]   1.16 ( 0.99, 1.36)
 Nagaya, 2010 [14]   1.45 ( 1.37, 1.53)
 Zhang, 2010 [13]   1.30 ( 1.15, 1.47)
 Shigetoh, 2009 [12]   1.62 ( 1.10, 2.37)
 Carnethon, 2008 [11]   1.00 ( 0.96, 1.05)
 Carnethon, 2006 [10]   1.12 ( 1.05, 1.21)
 Nilsson, 2004 [9]   1.13 ( 0.99, 1.30)
 Carnethon, 2003 [8]   1.06 ( 1.00, 1.13)
 Feskens, 1989 [6]   1.34 ( 1.08, 1.67)
 Overall   1.20 ( 1.07, 1.34)
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Supplementary Table 1: Resting heart rate and type 2 diabetes, nonlinear dose-response 
Beats per minute RR (95% CI) 
51a 1.00 
55 1.26 (1.17-1.35) 
60 1.59 (1.39-1.82) 
65 1.91 (1.59-2.29) 
70 2.18 (1.77-2.68) 
75 2.39 (1.92-2.99) 
80 2.52 (2.01-3.17) 
85 2.57 (2.03-3.24) 
90 2.53 (1.97-3.25) 
a
 The reference category was the lowest estimated midpoint among the included studies.  
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Supplementary Table 2: Newcastle-Ottawa quality score for individual studies 
Author, 
publication 
year 
Representativeness 
of the exposed 
cohort 
Selection 
of the 
non-
exposed 
cohort 
Ascertainment 
of exposure 
 
Demonstration 
that outcome 
of interest was 
not present at 
start of study 
Comparability 
of cohorts on 
the basis of the 
design or 
analysis 
(adjusted for 
age) 
Comparability 
of cohorts on 
the basis of the 
design or 
analysis 
(adjusted for 
any other 
factor) 
Assessment 
of outcome 
Was follow-
up long 
enough for 
outcomes to 
occur 
Adequacy 
of follow-
up of 
cohorts 
 
Total  
Grantham, 
2013 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
0 
 
8 
 
Nagaya, 
2010 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
0 
 
8 
 
Zhang, 2010 1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
0 
 
1 0 
 
7 
 
Shigetoh, 
2009 
1 
 
1 
 
1 
 
0 
 
1 
 
1 
 
0 
 
1 
 
0 
 
6 
 
Carnethon, 
2008 
1 1 1 1 1 1 1 1 0 8 
Carnethon, 
2006 
0 
 
1 
 
1 
 
0 
 
1 
 
1 
 
0 
 
1 
 
0 
 
5 
 
Nilsson, 
2004 
1 
 
1 
 
1 
 
0 
 
1 
 
1 
 
1 
 
1 
 
0 
 
7 
 
Carnethon, 
2003 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
0 
 
8 
 
Perry, 1995 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
9 
 
Feskens, 
1989 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
1 
 
0 
 
8 
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Supplementary Figure 1. Resting heart rate and type 2 diabetes, high vs. low analysis 
 
 
 
 
 
 
Supplementary figure 2. Funnel plot of resting heart rate and type 2 diabetes 
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